Abstract

Neuroglobin, a member of the globin superfamily, is abundant in the brain, retina and cerebellum of mammals and localizes to mitochondria. The protein exhibits neuroprotective capacities by participating to electron transfer, oxygen supply and protecting against oxidative stress. Our objective is to determine whether Neuroglobin overexpression can be used to treat neurological disorders. We chose Harlequin mice, which harbor a retroviral insertion in the first intron of the Apoptosis Inducing Factor gene resulting in the depletion of the corresponding protein essential for mitochondrial biogenesis. Consequently, Harlequin mice display degeneration of the cerebellum and suffer from progressive blindness and ataxia. Cerebellar ataxia begins in Harlequin mice at the age of four months and is characterized by neuronal cell disappearance, bioenergetics failure, motor and cognitive impairments which aggravated with aging. Mice aged two months received Adeno-Associated Viral vectors harboring the coding sequence of Neuroglobin or Apoptosis-inducing factor in both cerebellar hemispheres. Six months later, Harlequin mice exhibited substantial improvements in motor and cognitive skills; probably linked to the preservation of respiratory chain function, Purkinje cell numbers and connectivity. Thus, without sharing functional properties with Apoptosis-inducing factor, neuroglobin was efficient to reduce ataxia in Harlequin mice.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.